Loading organizations...
Kos Biotechnology Partners is an Athens, Greece-based venture capital firm, operating as Greece's first dedicated fund in life sciences. Founded in 2025 by Dr. Simos Simeonidis, who serves as Managing Partner, CEO, and CIO, and Co-Founder Alex Tzoukas, the firm partners with global experts and visionary founders. They provide strategic capital, operational expertise, and long-term support to build and scale high-impact platforms, products, and services within biotechnology, pharmaceuticals, and related fields. The firm targets breakthrough innovations across various stages, from seeding to growth, addressing critical needs. In January 2026, Kos Biotechnology Partners announced its inaugural investment, leading a financing round in Epikast, a tech-enabled pharma services provider, with Alex Tzoukas joining its board. Its business model centers on venture capital firm raising and deploying funds to invest in life sciences companies across various stages, from seeding to scaling.
The firm aims to cultivate a robust regional ecosystem for life sciences innovation by strategically partnering with global experts. It invests in companies developing groundbreaking solutions within the biotechnology and life sciences sectors.
The firm aims to cultivate a robust regional ecosystem for life sciences innovation by strategically partnering with global experts. It invests in companies developing groundbreaking solutions within the biotechnology and life sciences sectors.
Kos Biotechnology Partners is a venture capital firm founded in 2024, with a dedicated focus on the biotechnology and life sciences sectors. The firm is distinguished as the first Greece-based VC firm committed to these specialized fields. Its overarching mission is to foster a thriving regional ecosystem for life sciences innovation.
To achieve its ecosystem-building objectives, Kos Biotechnology Partners engages in strategic partnerships with global experts. This collaborative approach is central to its investment philosophy, enabling the firm to identify and support promising companies that are developing groundbreaking solutions and technologies within the life sciences. The firm's activities are geared towards advancing medical and biological research and applications.
The firm's investment scope encompasses a range of companies operating across the life sciences landscape. Notable portfolio companies include Epikast, which has received funding from Kos Biotechnology Partners, and Intelligencia AI. These investments reflect the firm's commitment to supporting ventures that demonstrate potential for significant impact and growth in their respective domains.
While established as a Greece-based entity, Kos Biotechnology Partners maintains a global outlook through its expert partnerships, indicating a strategy that combines regional development with international collaboration. Individuals such as Angelos Spiliopoulos are associated with the firm, contributing to its operational and strategic direction. The firm's presence in the venture capital landscape signifies a growing interest and investment in the life sciences sector within the region.
Kos Biotechnology Partners has 1 tracked investment across 1 company. The latest tracked deal is $2.2M Series B in Epikast in January 2026.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Jan 30, 2026 | Epikast | $2.2M Series B | KOS Biotechnology Partners | — |
